Skip to main content

Advertisement

Log in

Latent tuberculosis infection: diagnostic update before introduction of biological drugs

  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. WHO Online Tuberculosis Database. www.who.int/tb/country/ data/profiles (Accesed 21.07.15).

  2. García-Casalla M, Fernández-Baca V, Juan-Mas A, et al. Use of Quantiferon-TB-Gold in Tube® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. Enferm Infecc Microbiol Clin 2013; 31: 76–81.

    Article  Google Scholar 

  3. Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol 2014; 171: 884–90.

    Article  CAS  PubMed  Google Scholar 

  4. Hewitt RJ, Francis M, Singanayagam A, Min Kon O. Screening tests for tuberculosis before starting biological therapy. BJM 2015; 350: h1060.

    Article  Google Scholar 

  5. Latorre I, Carrascosa JM, Vilavella M, et al. Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis. J Infect 2014; 69: 600–6.

    Article  CAS  PubMed  Google Scholar 

  6. Mir-Viladrich I, Daudén-Tello E, Solano-López G, et al. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol 2016; 52: 36–45.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Antonio Martinez-Lopez.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martinez-Lopez, A., Ruiz-Villaverde, R. Latent tuberculosis infection: diagnostic update before introduction of biological drugs. Eur J Dermatol 26, 307–308 (2016). https://doi.org/10.1684/ejd.2016.2750

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2016.2750

Navigation